Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885207 | 0.81 | HDAC3 (0.56) | MAPTSCN8AHDAC3HDAC4HDAC1 | |
| SCHEMBL5316014 | 0.77 | HDAC3 (0.61) | TSHRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10856250 | 0.74 | KMT2A (0.64) | TSHRLMNAMAPK1ALDH1A1MAPT | |
| SCHEMBL2978233 | 0.72 | SCN8A (0.55) | MAPK1ALDH1A1POLBTP53TDP1 | |
| SCHEMBL7097610 | 0.72 | SCN8A (0.58) | MAPK1ALDH1A1POLBTP53TDP1 | |
| SCHEMBL10857113 | 0.72 | ALDH1A1 (0.53) | TSHRMAPK1ALDH1A1POLBTP53 | |
| SCHEMBL5320248 | 0.70 | HDAC3 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Acetamide SCHEMBL11092139 | 0.70 | KMT2A (0.51) | TSHRLMNAMAPK1ALDH1A1MAPT | |
| SCHEMBL4883748 | 0.69 | HDAC6 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12081120 | 0.69 | TSHR (0.46) | TSHRLMNAMAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1819669-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | HDAC1, HDAC10, HDAC6 | TSHR 3237/4885LMNA 1567/4885MAPK1 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.